Results: All patients completed the hyper-CVDD treatment as per protocol. Nine patients had B cell and two had T cell ALL. Four patients (28.6%) had mixed phenotype acute leukemia B + myeloid (n=2), T + myeloid (n=1), and B + T (n=1). Six patients (42.9%) were positive for BCR/ABL transcript and received tyrosine kinase inhibitor until transplantation. A total of 14 patients were enrolled in the trial. If the study patients were less than 65 years of age and achieved CR, they proceeded to allo-HCT after one course of consolidation chemotherapy. Daunorubicin was administrated on days 4, 11, and 12 at a dose of 45 mg/m 2/day. From the standard hyper-CVAD regimen, doxorubicin was replaced with daunorubicin.
#THE EYES OF ARA MAC TORRENT TRIAL#
Methods: We conducted a pilot trial of frontline remission induction using daunorubicin-augmented hyper-CVAD regimen (hyper-CVDD) in adult ALL patients (n=14). Based on these observations, a pilot trial was conducted with adult ALL patients using a daunorubicin-augmented hyper-CVAD (hyper-CVDD) regimen in which the doxorubicin in the standard hyper-CVAD regimen was replaced with an increased dose of daunorubicin to improve the efficacy of the regimen. Prior studies suggest that daunorubicin has a lower frequency of cardiomyopathy and other severe complications in leukemia patients than doxorubicin, and that a high induction dose of daunorubicin could contribute to a favorable treatment outcome in adult ALL patients.
This combination regimen showed a CR rate of 74% and mortality of 6% after one course of therapy (cycle 1).
Hyper-CVAD chemotherapy is one of the widely-used frontline remission induction regimens for these patients. Konkuk University Medical Center, Konkuk University School of Medicine, Seoul, Korea, Republic ofīackground: Induction of complete remission (CR) is imperative for long-term survival in adult acute lymphoblastic leukemia (ALL) patients who are eligible for transplantation. P001 A pilot study of daunorubicin-augmented hyper-CVAD induction chemotherapy followed by allogeneic hematopoietic cell transplantation for adults with acute lymphoblastic leukemia Sung-Yong Kim, Ji Hyun Park, So Young Yoon, Yo-Han Cho, Mark Hong Lee
0 kommentar(er)
